UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
__________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 6, 2008
AngioDynamics,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
000-50761
|
11-3146460
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
603
Queensbury Avenue, Queensbury, New
York 12804
|
(Address
of Principal Executive
Offices) (Zip
Code)
|
|
(518)
798-1215
|
(Registrant’s
telephone number, including area
code)
|
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c))
|
Item
7.01 – Regulation FD Disclosure.
On March 6, 2008, the Company issued a
press release, a copy of which is attached as Exhibit 99.1, announcing its
preliminary net sales for its fiscal third quarter ended February 29, 2008 and
revised its previously disclosed guidance with respect to expected fourth fiscal
quarter and full year fiscal 2008 sales. The Company expects to
release financial results for the fiscal third quarter after the close of the
financial markets on April 2, 2008 and will host a conference call in the same
afternoon.
Forward-Looking
Statements
This document and its attachments
include "forward-looking statements" intended to qualify for the safe harbor
from liability established by the Private Securities Litigation Reform Act of
1995. Investors can identify these statements by the fact that they do not
relate strictly to historical or current facts. These statements contain words
such as "expect," "reaffirm," "anticipate," "plan," "believe," "estimate,"
"may," "will," "predict," "project," "might," "intend," "potential," "could,"
"would," "should," "estimate," "seek," "continue," "pursue," or "our future
success depends," or the negative or other variations thereof or comparable
terminology, are intended to identify such forward-looking statements. In
particular, they include statements relating to, among other things, future
actions, strategies, future performance, future financial results of the
Company. These forward-looking statements are based on current expectations and
projections about future events.
Investors are cautioned that
forward-looking statements are not guarantees of future performance or results
and involve risks and uncertainties that cannot be predicted or quantified and,
consequently, the actual performance or results of the Company may differ
materially from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, but are not limited to, the factors
described from time to time in the Company's reports filed with the SEC,
including the Company's Form 10-K for the fiscal year ended June 2, 2007 and
Form 10-Q for the period ended November 30, 2007, financial community and rating
agency perceptions of the Company; the effects of economic, credit and capital
market conditions on the economy in general, and on medical device companies in
particular; domestic and foreign health care reforms and governmental laws and
regulations; third-party relations and approvals, technological advances and
patents attained by competitors; and challenges inherent in new product
development, including obtaining regulatory approvals. In addition to the
matters described above, the ability of the Company to develop its products,
future actions by the FDA or other regulatory agencies, results of pending or
future clinical trials, overall economic conditions, general market conditions,
market acceptance, foreign currency exchange rate fluctuations, and the effects
on pricing from group purchasing organizations and competition, may affect the
actual results achieved by the Company.
Any forward-looking statements are made
pursuant to the Private Securities Litigation Reform Act of 1995 and, as such,
speak only as of the date made. Investors are cautioned not to place
undue reliance on these forward-looking statements which speak only as of the
date stated, or if no date is stated, as of the date of this
document. The Company does not assume any obligation to publicly
update or revise any forward-looking statements at any time for any
reason.
Item
9.01 – Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated March 6, 2008.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
ANGIODYNAMICS,
INC.
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
Date: March
6, 2008
|
By:
|
/s/
Joseph Gersuk
|
|
|
|
|
Joseph
Gersuk
|
|
|
|
|
Chief
Financial Officer
|
|